Skip to main content

18-06-2020 | Adult-onset Still's disease | News


FDA approves canakinumab for adult-onset Still’s disease

Claire Barnard

medwireNews: The US FDA has expanded the indication for the interleukin (IL)-1 inhibitor canakinumab to include adult-onset Still’s disease (AOSD).

“Prior to today’s approval, patients had no FDA-approved treatments for their disease, which can include symptoms such as painful arthritis, fevers and rash,” said the FDA’s Nikolay Nikolov in a press release.

Canakinumab was previously approved for systemic juvenile idiopathic arthritis (sJIA), and the FDA notes “considerable overlap” between sJIA and AOSD, with IL-1 having an important role in the pathophysiology of both conditions.

The approval of canakinumab was based on extrapolation of the established efficacy of the IL-1 inhibitor in sJIA, as well as studies demonstrating its safety in AOSD and other conditions, and the drug was granted a Priority Review designation.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.